RU2008140661A - APPLICATION OF ANTIBODY FOR TREATMENT OF AUTOIMMUNE DISEASES IN A PATIENT WITH AN INadequate RESPONSE TO TNF-ALPH INHIBITOR - Google Patents
APPLICATION OF ANTIBODY FOR TREATMENT OF AUTOIMMUNE DISEASES IN A PATIENT WITH AN INadequate RESPONSE TO TNF-ALPH INHIBITOR Download PDFInfo
- Publication number
- RU2008140661A RU2008140661A RU2008140661/14A RU2008140661A RU2008140661A RU 2008140661 A RU2008140661 A RU 2008140661A RU 2008140661/14 A RU2008140661/14 A RU 2008140661/14A RU 2008140661 A RU2008140661 A RU 2008140661A RU 2008140661 A RU2008140661 A RU 2008140661A
- Authority
- RU
- Russia
- Prior art keywords
- mammal
- antibody
- use according
- week
- response
- Prior art date
Links
- 208000023275 Autoimmune disease Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 241000124008 Mammalia Species 0.000 claims 7
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 2
- 239000003246 corticosteroid Substances 0.000 claims 2
- 229960001334 corticosteroids Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229960000485 methotrexate Drugs 0.000 claims 2
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 claims 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 238000011970 concomitant therapy Methods 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000003628 erosive effect Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229960004584 methylprednisolone Drugs 0.000 claims 1
- 229960005205 prednisolone Drugs 0.000 claims 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 229960004641 rituximab Drugs 0.000 claims 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 claims 1
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 claims 1
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
1. Применение антитела, которое связывается с CD20, для производства лекарственного средства для лечения ревматоидного артрита у млекопитающего с неадекватным ответом на ингибитор TNFα, при котором млекопитающее имеет ACR50 ответ на 24-й неделе, ACR70 ответ на 24-й неделе или не имеет прогрессивного развития эрозий на 24-й неделе и далее. ! 2. Применение по п.1, в котором млекопитающим является человек. ! 3. Применение по п.1, в котором антитело не конъюгировано с цитотоксическим агентом. ! 4. Применение по п.1, в котором антителом является ритуксимаб. ! 5. Применение по п.1, в котором антитело является гумманизированным антителом 2Н7 v16, содержащим вариабельные домены, представленные SEQ ID Nos. 1 и 2. ! 6. Применение по п.1, при котором лекарственное средство применяется для лечения млекопитающего в способе, который, по существу, заключается во введении млекопитающему антагониста. ! 7. Применение по п.1, при котором антитело вводится в качестве двух внутривенных доз по 1000 мг. ! 8. Применение по п.1, при котором млекопитающее дополнительно получают сопутствующую терапию метотрексатом (МТХ). ! 9. Применение по п.8, при котором млекопитающее дополнительно лечат кортикостероидами. ! 10. Применение по п.9, при котором кортикостероиды включают метилпреднизолон и преднизолон. 1. The use of an antibody that binds to CD20 for the manufacture of a medicament for the treatment of rheumatoid arthritis in a mammal with an inadequate response to a TNFα inhibitor in which the mammal has an ACR50 response at week 24, an ACR70 response at week 24, or is not progressive the development of erosion in the 24th week and beyond. ! 2. The use according to claim 1, in which the mammal is a human. ! 3. The use according to claim 1, in which the antibody is not conjugated to a cytotoxic agent. ! 4. The use according to claim 1, in which the antibody is rituximab. ! 5. The use according to claim 1, in which the antibody is a humanized antibody 2H7 v16 containing the variable domains represented by SEQ ID Nos. 1 and 2.! 6. The use according to claim 1, wherein the drug is used to treat a mammal in a method which essentially consists in administering an antagonist to the mammal. ! 7. The use according to claim 1, wherein the antibody is administered as two intravenous doses of 1000 mg. ! 8. The use according to claim 1, in which the mammal additionally receive concomitant therapy with methotrexate (MTX). ! 9. The use of claim 8, wherein the mammal is further treated with corticosteroids. ! 10. The use of claim 9, wherein the corticosteroids include methylprednisolone and prednisolone.
Claims (10)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60/461,481 | 2003-04-09 | ||
| US46148106P | 2006-04-09 | 2006-04-09 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005134394/14A Division RU2358762C9 (en) | 2003-04-09 | 2004-04-06 | Treatment of autoimmune diseases in patient suffering from inadequate response to tnf-alpha inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2008140661A true RU2008140661A (en) | 2010-04-20 |
| RU2489166C2 RU2489166C2 (en) | 2013-08-10 |
Family
ID=46274896
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008140661/15A RU2489166C2 (en) | 2006-04-09 | 2008-10-14 | Using antibodies for treating autoimmune diseases in patient with inadequate response to tnf-alpha inhibitor |
Country Status (1)
| Country | Link |
|---|---|
| RU (1) | RU2489166C2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2639540C2 (en) * | 2011-08-10 | 2017-12-21 | Ланкенау Инститьют Фо Медикал Ресёрч | Methods and compositions for autoimmune and inflammatory diseases treatment |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2724469C2 (en) | 2018-10-31 | 2020-06-23 | Закрытое Акционерное Общество "Биокад" | Monoclonal antibody which specifically binds to cd20 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996012741A1 (en) * | 1994-10-25 | 1996-05-02 | Glaxo Group Limited | Binding agents to cd23 |
| US5677189A (en) * | 1995-06-29 | 1997-10-14 | Oncomembrane, Inc. | Method for quantifying sphingosine and for diagnosing platelet activation |
| JP2001058956A (en) * | 1999-08-19 | 2001-03-06 | Welfide Corp | Autoimmune disease prevention / treatment agent |
-
2008
- 2008-10-14 RU RU2008140661/15A patent/RU2489166C2/en active
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2639540C2 (en) * | 2011-08-10 | 2017-12-21 | Ланкенау Инститьют Фо Медикал Ресёрч | Methods and compositions for autoimmune and inflammatory diseases treatment |
Also Published As
| Publication number | Publication date |
|---|---|
| RU2489166C2 (en) | 2013-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6623736B2 (en) | Interleukin antagonists for the treatment of neurological, retinal and muscular disorders | |
| Tanaka et al. | A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus | |
| US20200147084A1 (en) | Tec family kinase inhibitor adjuvant therapy | |
| CN104039320B (en) | Treatment of hematological malignancies with anti-CXCR4 antibodies | |
| Mok | Therapeutic options for resistant lupus nephritis | |
| CN114286828A (en) | Dosing regimens and combination therapies for multispecific antibodies targeting B cell maturation antigens | |
| JP2004512262A5 (en) | ||
| JP2014114288A5 (en) | ||
| JP2002537356A (en) | Tumor necrosis factor antagonist for treatment of neuropathy | |
| JP2020508317A5 (en) | ||
| JP2022160685A5 (en) | ||
| RU2007132181A (en) | ANTI-CANCER MEDICINE CONTAINING α, α, α-TRIFTORTIMIDINE AND A THIMIDINFOSPHORILYLASE INHIBITOR | |
| CA2939464A1 (en) | Use of anti-ccr5 antibodies in graft versus host disease | |
| WO2018223923A1 (en) | Use of pd-1 antibody combined with vegf ligand or vegf receptor inhibitor in preparing drug for treating tumor | |
| JP2018515493A5 (en) | ||
| JP2015172060A5 (en) | ||
| HK1213782A1 (en) | Pharmaceutical composition, comprising an anti-cd6 monoclonal antibody used in the diagnosis and treatment of rheumatoid arthritis | |
| RU2016149316A (en) | TREATMENT OF RHEUMATOID ARTHRITIS | |
| PE20061075A1 (en) | ANTI-VEGF ANTIBODIES AS ANTIANGIOGENIC AGENTS TO TREAT AUTOIMMUNE DISEASES IN PATIENTS IN WHOM PREVIOUS THERAPY FAILED | |
| RU2011117293A (en) | COMPOSITION FOR TREATING A DISEASE | |
| FI3630177T3 (en) | Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment | |
| KR20180017145A (en) | Treatment of pruritus | |
| RU2008140661A (en) | APPLICATION OF ANTIBODY FOR TREATMENT OF AUTOIMMUNE DISEASES IN A PATIENT WITH AN INadequate RESPONSE TO TNF-ALPH INHIBITOR | |
| EP4424709A3 (en) | Dosing regimen for anti-bcma agents | |
| WO2020242923A1 (en) | Uses of radiation and benzodiazepine derivatives in cancer therapies |